Loading
institutionsInstitution
Swissmedic
Swissmedic authorises medicines and devices in Switzerland and Liechtenstein; because Switzerland sits outside the EU it runs its own approvals, but it shares work with the FDA through Project Orbis and the Access Consortium and relies on decisions by comparable regulators.
Also called: Swiss Agency for Therapeutic Products
Overview
Established in 2002, Swissmedic authorises and supervises medicines and medical devices in Switzerland and Liechtenstein. Because Switzerland sits outside the EU, it runs its own approval process, and it has joined international work-sharing through the FDA's Project Orbis, the Access Consortium and reliance procedures for products already approved by comparable regulators. It offers fast-track and temporary authorisation for medicines against serious diseases and regulates the advanced therapies produced by the Swiss pharmaceutical industry. Pricing and reimbursement are decided separately by the Federal Office of Public Health.
Location
Bern, CH
Type
government
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#548 · 6 points (0 Newsweek + 0 NCI + 6 from 3 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-17.
Matched to Swissmedic, including child institutions. 4 works · 2 citations · 100% open access · 0% clinical trials · 0% reviews.
Oncology works per year
02022
12023
02024
12025
22026
Most works
- Mirjam Schenk1 works
- Lara Valeska Maul1 works
- Thomas Stammschulte1 works
- Max Nobis1 works
- Kaspar Z’graggen1 works
- Beat Damke1 works
- Rodolfo Rascon De Lira1 works
- Ulf Kessler1 works
- Steve Robatel1 works
- Ralph P. Braun1 works
Most cited
| Work | Journal | Year | Citations |
|---|---|---|---|
| Prevalence of substances with OATP1B1 inhibitory properties in individual case safety reports of suspected statin-associated myopathy – an analysis of Swiss pharmacovigilance data 10.1007/s00228-025-03968-7 · open access | European Journal of Clinical Pharmacology | 2026 | 2 |
| Agonistic GITR treatment enhances antitumor immune responses and suppresses tumor progression in pancreatic ductal adenocarcinoma 10.1007/s00535-026-02347-y · open access | Journal of Gastroenterology | 2026 | 0 |
| Teledermatological services at a Swiss university hospital - evaluation of patient benefits and economic impact 10.1080/09546634.2025.2555189 · open access | Journal of Dermatological Treatment | 2025 | 0 |
| Leucopénie: un effet indésirable rare sous amitriptyline 10.4414/fms.2023.09292 · open access | Forum Médical Suisse ‒ Swiss Medical Forum | 2023 | 0 |
- Marketing authorisation and fast-track procedures
- Project Orbis and Access Consortium
- Reliance on foreign approvals
- Market surveillance
Similar pages
- IdeaDrop the extra switching studies for interchangeable oncology biosimilars
Shares European Medicines Agency, FDA Oncology Center of Excellence, Regulatory divergence between regions.
- CollectionEMA news and CHMP meeting highlights
Shares European Medicines Agency, FDA Oncology Center of Excellence.
- InstitutionComisión Federal para la Protección contra Riesgos Sanitarios
Shares European Medicines Agency, FDA Oncology Center of Excellence, Regulatory divergence between regions.
- InstitutionBundesinstitut für Arzneimittel und Medizinprodukte
Shares Medicines and Healthcare products Regulatory Agency, European Medicines Agency, Regulatory divergence between regions.
- InstitutionACCELERATE
Shares European Medicines Agency, FDA Oncology Center of Excellence, Regulatory divergence between regions.
- InstitutionPaul-Ehrlich-Institut
Shares European Medicines Agency, Regulatory divergence between regions.
- InstitutionPharmaceuticals and Medical Devices Agency
Shares European Medicines Agency, FDA Oncology Center of Excellence, Regulatory divergence between regions.
- TermICH good clinical practice (E6)
Shares European Medicines Agency, FDA Oncology Center of Excellence, Regulatory divergence between regions.